Assessment of mycn amplification status in tunisian neuroblastoma: cisH and mlPa combining approach.
##plugins.themes.academic_pro.article.main##
Abstract
SUMMARY
Background: Neuroblastoma (NB) shows a complex combination of genetic aberrations. Some of them represent poor genetic prognosis factors that require specific and intensive chemotherapy. MYCN amplification consists of the major bad outcome prognostic factor, it is indeed frequently observed in aggressive neuroblastomas. To date different methods are used for MYCN status detection.
Objectives: The primary aim of our study was to provide a critical assessment of MYCN status using 2 molecular techniques CISH and MLPA. We also focused on the correlation between neuroblastoma genetic markers and patient’s clinical course among 15 Tunisian patients.
Methods: we developed a descriptive study that includes 15 pediatric Tunisian patients referred to our laboratory from 2004 to 2011. We reported the analysis of fresh and FFPE NB tumors tissues.
Results: No significant correlation was found between COG grade and patients overall survival. Assessment of NMYC gene copy number by kappa statistic test revealed high concordance between CISH and MLPA tests (kappa coefficient = 0.02).
Conclusion: Despite misdiagnosing of MYCN status fewer than 5 copies, MLPA remains an effective molecular technique that enables a large panel of genomic aberrations screening. Thus combining CISH and MLPA is an effective molecular approach adopted in our laboratory. Our results allow pediatric oncologists to set up the first Neuroblastoma therapeutic strategy based on molecular markers in Tunisia.
Background: Neuroblastoma (NB) shows a complex combination of genetic aberrations. Some of them represent poor genetic prognosis factors that require specific and intensive chemotherapy. MYCN amplification consists of the major bad outcome prognostic factor, it is indeed frequently observed in aggressive neuroblastomas. To date different methods are used for MYCN status detection.
Objectives: The primary aim of our study was to provide a critical assessment of MYCN status using 2 molecular techniques CISH and MLPA. We also focused on the correlation between neuroblastoma genetic markers and patient’s clinical course among 15 Tunisian patients.
Methods: we developed a descriptive study that includes 15 pediatric Tunisian patients referred to our laboratory from 2004 to 2011. We reported the analysis of fresh and FFPE NB tumors tissues.
Results: No significant correlation was found between COG grade and patients overall survival. Assessment of NMYC gene copy number by kappa statistic test revealed high concordance between CISH and MLPA tests (kappa coefficient = 0.02).
Conclusion: Despite misdiagnosing of MYCN status fewer than 5 copies, MLPA remains an effective molecular technique that enables a large panel of genomic aberrations screening. Thus combining CISH and MLPA is an effective molecular approach adopted in our laboratory. Our results allow pediatric oncologists to set up the first Neuroblastoma therapeutic strategy based on molecular markers in Tunisia.
Keywords:
Neuroblastoma, MYCN, CISH, Prognosis, Genetics##plugins.themes.academic_pro.article.details##
References
- Perel Y, Valteau-Couanet D, Michon J et al. [Prognosis of neuroblastoma in childhood. Methods of assessment and clinical use]. Arch Pediatr 2004;11;834-842.
- Brodeur GM, Pritchard J, Berthold F et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993;11;1466-1477.
- Freeman-Edward J, O'Neill S, Lastowska M, Bown N. Expulsion of amplified MYCN from neuroblastoma tumor cells. Cancer Genet Cytogenet 2000;116;87-88.
- Brodeur GM, Sekhon G, Goldstein MN. Chromosomal aberrations in human neuroblastomas. Cancer 1977;40;2256-2263.
- Spitz R, Hero B, Simon T, Berthold F. Loss in chromosome 11q identifies tumors with increased risk for metastatic relapses in localized and 4S neuroblastoma. Clin Cancer Res 2006;12;3368-3373.
- Plantaz D. [Neuroblastoma a century after Pepper: which are the genes?]. Arch Pediatr 2001;8;917-921.
- Villamon E, Piqueras M, Mackintosh C et al. Comparison of different techniques for the detection of genetic risk-identifying chromosomal gains and losses in neuroblastoma. Virchows Arch 2008;453;47-55.
- Okamatsu C, London WB, Naranjo A et al. Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: a report from the CCG and COG. Pediatr Blood Cancer 2009;53;563-569.
- Yoo SB, Lee HJ, Park JO et al. Reliability of chromogenic in situ hybridization for epidermal growth factor receptor gene copy number detection in non-small-cell lung carcinomas: a comparison with fluorescence in situ hybridization study. Lung Cancer 2009;67;301-305.
- Paul S. Thorner a b, Michael Ho a, Maria Zielenska a,b. Chromogenic in situ hybridization using routine tissue sections: MYCN in neuroblastoma. Asian Biomedicine 2007;1.
- Kato N, Itoh H, Serizawa A, Hatanaka Y, Umemura S, Osamura RY. Evaluation of HER2 gene amplification in invasive breast cancer using a dual-color chromogenic in situ hybridization (dual CISH). Pathol Int 2010;60;510-515.
- Garcia-Caballero T, Prieto O, Vazquez-Boquete A et al. Dual-colour CISH is a reliable alternative to FISH for assessment of topoisomerase 2-alpha amplification in breast carcinomas. Breast Cancer Res Treat 2014;143;81-89.
- Combaret V, Iacono I, Brejon S et al. Analysis of genomic alterations in neuroblastoma by multiplex ligation-dependent probe amplification and array comparative genomic hybridization: a comparison of results. Cancer Genet 2012;205;657-664.